Pay in 4 interest-free payments of $7.46 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
janur 22
A PDE6-KRas inhibitor chemotype with up to seven H-bonds and picomolar affinity that prevents efficient inhibitor release by Arl2
Key distinctions include: Dual diagnosis typically requires specialized addiction treatment alongside mental health care Co-occurring disorders may need various therapeutic approaches working in tandem Treatment timing and sequencing vary between the two conditions significantly Medication management strategies differ based on specific substance use patterns Support group recommendations change based on specific diagnosis combinations Treatment intensity levels may vary throughout the recovery process Recovery milestones often need individualized definitions Why It's Important to Understand the Difference Impact on Treatment Plans The distinction between these conditions directly affects treatment success
doi: 10.1111/j.1463-1326.2011.01467.x
US$ 26.63
US$ 24.69
US$ 24.79
